The effects of the vascular disrupting agents combretastatin A-4 disodium phosphate, 5,6-dimethylxanthenone-4-acetic acid and ZD6126 in a murine tumour: A comparative assessment using MRI and MRS

Acta Oncologica

Volumn 45, Issue 3, 2006, Pages 306-316

  Breidahl, Tomas ^a,b   Nielsen, Flemming U ^b,c   Stødkilde JØrgensen, Hans ^b   Maxwell, Ross J ^b,d   Horsman, Michael R ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

^c MRI Department   (Italy)

^d MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; CA4DP; COMBRETASTATIN A4 PHOSPHATE; N ACETYLCOLCHINOL PHOSPHATE; VASCULAR TARGETING AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLEEDING; BREAST CARCINOMA; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFUSION WEIGHTED IMAGING; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFECT; EDEMA; FEMALE; INTERMETHOD COMPARISON; MOUSE; NON INVASIVE MEASUREMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; TISSUE NECROSIS;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; FEMALE; HYDROGEN-ION CONCENTRATION; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, INBRED C3H; NUCLEOSIDES; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHATES; STILBENES; TIME FACTORS; TREATMENT OUTCOME; XANTHONES;

EID: 33646417630     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860600570465     Document Type: Article

References (52)

1. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002;29(Suppl 16):15-8.
2. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: A review. Cancer Res 1989;49:6449-65.
3. Horsman MR, Overgaard J. The oxygen effect and the tumour microenvironment. In: Steel GG, editor. Basic Clinical Radiobiology for Radiation Oncologists. London: Edward Arnold; 2002. p. 158-68.
4. Siemann DW, Warrington KH, Horsman MR. Targeting tumor blood vessels; an adjuvant strategy for radiation therapy. Radiother Oncol 2000;57:5-12.
5. Folkman J. Angiogenesis inhibitors: A new class of drugs. Cancer Biol Ther 2003;2(4 Suppl 1):S127-33.
6. National Cancer Institute Website (www.cancer.gov/clinical trials).
7. Denekamp J. Vascular attack as a therapeutic strategy for cancer. Cancer Met Rev 1990;9:267-82.
8. Horsman MR, Murata R. Combination of vascular targeting agents with thermal or radiation therapy. Int J Radiat Oncol Biol Phys 2002;54:1518-23.
9. Siemann DW, Chaplin DJ, Horsman MR. Vascular targeting therapies for treatment of malignant disease. Cancer 2004;100:2491-9.
10. Pettit GR, Singh SB, Hamel E, Lin CM, Alberts DS, Garcia-Kendall D. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia 1989;45:209-11.
11. Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer 2005;5:423-35.
12. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumour vasculature. Cancer Res 1997;57:1829-34.
13. Murata R, Siemann DW, Overgaard J, Horsman MR. Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumours. Radiother Oncol 2001;60:155-61.
14. Blakey DC, Westwood FR, Walker M, Hughes GD, Davis PD, Ashton SE, et al. Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res 2002;8:1974-83.
15. Davis PD, Dougherty GJ, Blakey DC, Galbraith SM, Tozer GM, Holder AL, et al. ZD6126: Anovel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res 2002;62:7247-53.
16. Siemann DW, Rojiani AM. Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 2002;53:164-71.
17. Horsman MR, Murata R. Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response. Int J Radiat Oncol Biol Phys 2003;57:1047-55.
18. Ching LM, Joseph WR, Crosier KE, Baguley BC. Induction of tumor necrosis factor alpha messenger RNA in human and murine cells by the flavone acetic acid analogue 5,6 dimethylxanthenone-4-acetic acid. Cancer Res 1994;54:870-2.
19. Laws AL, Matthew AM, Double JA, Bibby MC. Preclinical in vitro and in vivo activity of 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 1995;71:1204-9.
20. Lash CJ, Li AE, Rutland M, Baguley BC, Zwi LJ, Wilson WR. Enhancement of the anti-tumour effects of the anti-vascular agent 5,6-dimethylxanthenone-4-acetic acid by combination with 5-hydroxytryptamine and bioreductive drugs. Br J Cancer 1998;78:439-45.
21. Murata R, Overgaard J, Horsman MR. Comporative effects of combretastain A-4 disodium phosphate an 5,6-dimethyl-xanthenon-4-acetic acid on blood perfusion in a murine tumour and normal tissus. Int J Radiat Biol 2001;77:195-204.
22. Murata R, Overgaard J, Horsman MR. Potentiation of the anti-tumor effect of hyperthermia by combining with the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid. Int J Hyperthermia 2001;17:508-19.
23. Maxwell RJ, Nielsen FU, Breidahl T, Stødkilde-Jørgensen H, Horsman MR. Effects of combretastatin on murine tumours monitored by 31P MRS, 1H MRS and 1H MRI. Int J Radiat Oncol Biol Phys 1998;42:891-4.
24. Overgaard J. Simultaneous and sequential hyperthermia and radiation treatment of an experimental tumor and its surrounding normal tissue in vivo. Int J Radiat Oncol Biol Phys 1980;6:1507-17.
25. Horsman MR, Sampson LE, Chaplin DJ, Overgaard J. The in vivo interaction between flavone acetic acid and hyperthermia. Int J Hyperthermia 1996;12:779-89.
26. 2 and radiation response in an experimental tumour model. Br J Cancer 1997;76:1432-9.
27. th annual meeting. Prague: 1996. p. 318.
28. Hill SA, Sampson LE, Chaplin DJ. Anti-vascular approaches to solid tumour therapy: Evaluation of vinblastine and flavone acetic acid. Int J Cancer 1995;63:119-23.
29. Grosios K, Holwell SE, McGown AT, Pettit GR, Bibby MC. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br J Cancer 1999;81:1318-27.
30. Evelhoch JL, LoRusso PM, He Z, DelProposto Z, Polin L, Corbett TH, et al. Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126. Clin Cancer Res 2004;10:3650-7.
31. Galbraith SM, Rustin GJ, Lodge MA, Taylor NJ, Stirling JJ, Jameson M, et al. Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol 2002;20:3826-40.
32. Galbraith SM, Maxwell RJ, Lodge MA, Tozer GM, Wilson J, Taylor NT, et al. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 2003;21:2831-42.
33. Maxwell RJ, Wilson J, Prise VE, Vojnovic B, Rustin GJ, Lodge MA, et al. Evaluation of the anti-vascular effects of combretastatin in rodent tumours by dynamic contrast enhanced MRI. NMR Biomed 2002;15:89-98.
34. Beauregard DA, Hill SA, Chaplin DJ, Brindle KM. The susceptibility of tumors to the antivascular drug combretastatin A4 phosphate correlates with vascular permeability. Cancer Res 2001;61:6811-5.
35. Beauregard DA, Pedley RB, Hill SA, Brindle KM. Differential sensitivity of two adenocarcinoma xenografts to the anti-vascular drugs combretastatin A4 phosphate and 5,6-dimethylxanthenone-4-acetic acid, assessed using MRI and MRS. NMR Biomed 2002;15:99-105.
36. Robinson SP, McIntyre DJO, Checkley D, Tessier JJ, Howe FA, Griffiths JR, et al. Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging. Br J Cancer 2003;88:1592-7.
37. Murata R, Siemann DW, Overgaard J, Horsman MR. Improved tumor response by combining radiation and the vascular-damaging drug 5,6-dimethylxanthenone-4-acetic acid. Radiat Res 2001;156:503-9.
38. McPhail LD, Chung Y-L, Madhu B, Clarke S, Griffiths JR, Kelland LR, et al. Tumor dose response to the vascular disrupting agent, 5,6-dimethylxanthenone-4-acetic acid, using in vivo magnetic resonance spectroscopy. Clin Cancer Res 2005;11:3705-13.
39. Nordsmark M, Grau C, Horsman MR, Støkilde-Jørgensen H, Overgaard J. Relationship between tumour oxygenation, bioenergetic status and radiobiological hypoxia in an experimental model. Acta Oncol 1995;34:329-34.
40. 4 prodrug-induced disruption of tumour perfusion and energetic status. Br J Cancer 1998;77:1761-7.
41. Raghunand N, Gillies RJ. pH and chemotherapy. In: Goode JA, Chadwick DJ, editors. The Tumour Microenvironment: Causes and Consequences of Hypoxia and Acidity. London: John Wiley and Sons; 2001. p. 199-211.
42. Overgaard J, Bichel P. The influence of hypoxia and acidity on the hyperthermic response of malignant cells in vitro. Radiol 1977;123:511-4.
43. Shi W, Horsman MR, Siemann DW. Combined modality approaches using vascular disrupting agents. In: Siemann DW, editor. Vascular-targeted Therapies in Oncology. London: John Wiley and Sons; (in press).
44. Chaplin DJ, Acker B, Olive PL. Potentiation of the tumor cytotoxicity of melphalan by vasodilating drugs. Int J Radiat Oncol Biol Phys 1989;16:1131-5.
45. Pruijn FB, van Daalen M, Holford NH, Wilson WR. Mechanism of enhancement of the antitumour activity of melphalan by the tumour-blood-flow inhibitor 5,6-dimethyl-xanthenone-4-acetic acid. Cancer Chemother Pharmacol 1997;39:541-6.
46. Dodd NJF, Moore JV, Poppitt DG, Wood B. In vivo magnetic resonance imaging of the effects of photodynamic therapy. Br J Cancer 1989;60:164-7.
47. Zwi LJ, Baguley BC, Gavin JB, Wilson WR. The morphological effects of the anti-tumor agents flavone acetic acid and 5,6-dimethyl xanthenone acetic acid on the colon 38 mouse tumor. Pathology 1994;26:161-9.
48. Ferrero E, Villa A, Ferrero ME, Toninelli E, Bender JR, Pardi R, et al. Tumor necrosis factor alpha-induced vascular leakage involves PECAM1 phosphorylation. Cancer Res 1996;56:3211-5.
49. Robinson SP, Kalber TL, Howe FA, McIntyre DJ, Griffiths JR, Blakey DC, et al. Acute tumor response to ZD6126 assessed by intrinsic susceptibility magnetic resonance imaging. Neoplasia 2005;7:466-74.
50. Carano RA, Ross AL, Ross J, Williams SP, Koeppen H, Schwall RH, et al. Quantification of tumor tissue populations by multispectral analysis. Magn Reson Med 2004;51:542-51.
51. Thoeny HC, De Keyzer F, Vandecaveye V, Chen F, Sun X, Bosmans H, et al. Effect of vascular targeting agent in rat tumor model: Dynamic contrast-enhanced versus diffusion-weighted MR imaging. Radiol 2005;237:492-9.
52. Padhani AR. MRI for assessing antivascular cancer treatments. Br J Radiol 2003;76:S60-80.